HIV infection-I

British Medical Journal

Volumn 314, Issue 7079, 1997, Pages 487-491

  Cohn, Jonathan Allen ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGOURON; ANTIVIRUS AGENT; DELAVIRDINE; MARKER; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

BLOOD LEVEL; DISEASE COURSE; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY DIAGNOSIS; OCCUPATIONAL EXPOSURE; PATIENT MONITORING; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; CLINICAL PROTOCOL; DRUG SCREENING; OCCUPATIONAL DISEASE;

ANTI-HIV AGENTS; CLINICAL PROTOCOLS; DRUG EVALUATION; HIV INFECTIONS; HUMANS; OCCUPATIONAL DISEASES;

EID: 0031568694     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Perelson AS, Neuman AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-6.
2. Perelson AS, Essunger P, Markowitz M, Ho DD. How long should treatment be given if we had an antiretroviral regimen that completely blocks HIV replication? XI International Conference on AIDS, Vancouver, 1996. (Abstract ThB930.)
3. Markowitz M, Cao Y, Jurley A, O'Donovan R, Heath-Chiozzi M, et al. Triple therapy with AZT, 3TC, and ritonavir in 12 subjects newly infected with HIV-1. XI International Conference on AIDS, Vancouver, 1996. (Abstract ThB933.)
4. Tindall B, Cooper DA. Primary HIV infection: host responses and intervention strategies. AIDS 1991;5:1-14.
5. Fauci A, Pantaleo G, Stanley S, Weissman D. Immunopathogenic mechanisms of HIV infection. Ann Intern Med 1996;124:654-63.
6. Pederson C, Katzenstein T, Nielsen C, Lundgren JC, Gerstoft J. Events in early HIV infection determine the long term outcome of the infection. XI International Conference on AIDS, Vancouver, 1996. (Abstract MoB1341.)
7. Munoz A, Margolick JB, Chu C, Donnenberg AD, Giorgi JV, Phair JP. Progression of HIV infection and stability of immunologic markers prior to and around seroconversion. XI International Conference on AIDS, Vancouver, 1996. (Abstract MoC322.)
8. Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombs R, Poscher ME, et al. HIV viral load markers in clinical practice. Nature Med 1996;2:625-9.
9. Mellors JW, Kingsley LA, Rinaldo JR. CR, Todd JA, Hoo BS, Kokka RP, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573-9.
10. Mellors JW, Rinaldo Jr. CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
11. Choi S, Lagakos SW, Schooley RG, Volberding PA. CD4 + lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med 1993;118:674-80.
12. O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S, et al. Changes in plasma HIV-1 RNA and CD4 + lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-31.
13. Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, et al. The relation of virologic, and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 400 CD4 cells per cubic millimeter. N Engl J Med 1996;335;1091-8.
14. Phillips AN, Eron J, Bartlett J, Hill AM. Effect of nucleoside analogue RT inhibitors on plasma HIV RNA and CD4 count as an indicator of clinical effect. XI International Conference on AIDS, Vancouver, 1996.(Abstract MoB290.)
15. Brun-Vezinet F, Delta Virology Group. HIV viral load changes in Delta patients. XI International Conference on AIDS, Vancouver 1996. (Abstract MoB292.)
16. Wathen LK, Nickens DJ, Chuang-Stein CJ, Crampton DJ, Mickelson PM, Carberry PA, et al. HIV-1 RNA viral burden at baseline or its reduction following antiretroviral therapy is highly correlated with reduced HIV-1 disease progression. 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1996. (Abstract LB8c.)
17. Levy JA. Surrogate markers in AIDS research. Is there truth in numbers? JAMA 1996;276:161-2.
18. Deyton L. Importance of surrogate markers in evaluation of antiviral therapy for HIV infection. JAMA 1996;276:159-60.
19. Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, Parniak MA et al. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 1996;71:1282-5.
20. Eron JJ, Benoit SH, Jemsek J, MacArthur RD, Santana J, Quinn JB, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4 + cells per cubic millimeter. N Engl J Med 1995;333:1662-9.
21. Katalama C, Ingrand D, Loveday C, Clumeck N, Mallolas J, Staszewski S, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. JAMA 1996;276:118-25.
22. Staszewski S, Loveday C, Picazo JJ, Dellamonica P, Skinhoj P, Johnson MA, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. JAMA 1996;276:111-7.
23. Staszewski S, Bartlett J, Eron J, Katlama C, Johnson J, Hill AM. Reductions in HIV-1 disease progression for AZT/3TC relative to control treatments: a meta analysis. XI International Conference on AIDS, Vancouver, 1996. (Abstract ThB948.)
24. Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Am Intern Med 1996;124:1039-1050.
25. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996;334: 1011-7.
26. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdez JM, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-9.
27. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, et al. A short-term study of the safety, pharmocokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995;333:1528-33.
28. Norvir (ritonavir capsules and oral solution) prescribing information. Chicago: Abbott Laboratories, 1996.
29. Cameron W, Sun E, Markowitz M, Farthing C, McMahon D, Poretz D, Cohen C, et al. Combination use of ritonavir and saquinavir in HIV-infected patients: preliminary safety and activity data. XI International Conference on AIDS, Vancouver, 1996. (Abstract ThB934.)
30. Cameron DW, Heath-Chiozzi M, Kravcik S, Mills R, Potthoff A, Henry D, et al. Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with ritonavir: update. XI International Conference on AIDS, Vancouver, 1996. (Abstract MoB411.)
31. Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL, Drusano GL. A 24-week open label phase I/II evaluation of the new HIV protease inhibitor MK-639 (indinavir). AIDS 1996;10:485-92.
32. Crixivan (indinavir sulfate) prescribing information. West Point, PA: Merck & Co, 1996.
33. Gulick RM, Mellors J, Havlir D, Eron J, Gonzalez C, McMahon D, et al. Potent and sustained antiretroviral activity of indinavir (IDV), zidovudine (ZDV) and lamivudine (3TC). XI International Conference on AIDS, Vancouver, 1996. (Abstract ThB931.)
34. Condra J, Holder DJ, Schleif WA, Chodakewitz JA, Massari FE, Blahy OM, et al. Bi-directional inhibition of HIV-1 drug resistance selection by combination therapy with indinavir and reverse transcriptase inhibitors. XI International Conference on AIDS, Vancouver. 1996. (Abstract ThB932.)
35. D'Aquila RT, Hughes MD, Johnson VA, Fischl MA, Sommadossi JP, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. Ann Intern Med 1996;124:1019-30.
36. Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995;337:450-1.
37. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. JAMA 1996;276:146-54.
38. Davey R, Kovacs J, Walker R, Polis M, Falloon J, et al. Subcutaneous interleukin-2 therapy is capable of inducing marked sustained increases in CD4 counts in early HIV-infected patients. XI International Conference on AIDS, Vancouver, 1996. (Abstract WeB290.)
39. Carr A, Lloyd A, Emery S, Hoy J, Garsia R, Stewart G, et al. A randomized, controlled trial of interleukin-2 (IL-2) or polyethylene glycol IL2 (PEG-IL2) plus antiretroviral therapy (AR) versus AR alone in HIV-infected patients with 200-500 CD4+ cells. XI International Conference on AIDS, Vancouver, 1996. (Abstract WeB292.)
40. Centers for Disease Control and Prevention. Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood - France, United Kingdom, and United States, January 1988-August 1994. MMWR 1995;44:929-31.
41. Centers for Disease Control and Prevention. Update: provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR 1996;45:468-72.
42. Beiser C. Recent advances in HIV infection. II. BMJ (in press).